Table S5. Univariate and multivariate analysis of predictive factor for OS and survival after the first progression post-SABR for PLLs.
| Characteristics | OS | Survival after the first progression post-SABR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Age (continuous) | 0.99 (0.94–1.04) | 0.79 | – | – | 1.01 (0.93–1.08) | 0.8 | – | – | |||
| Age | – | ||||||||||
| <70 years | 0.89 (0.34–2.31) | 0.81 | – | – | 1.37 (0.43–4.3) | 0.59 | – | ||||
| ≥70 years | – | – | – | – | – | – | – | ||||
| Gender | – | ||||||||||
| Male | 0.68 (0.23–1.94) | 0.47 | – | – | 0.54 (0.16–1.80) | 0.31 | – | ||||
| Female | – | – | – | – | – | – | – | ||||
| FEV1 (continuous) | 0.99 (0.98–1.01) | 0.85 | – | – | 1.00 (0.98–1.03) | 0.42 | – | – | |||
| FEV1 | – | ||||||||||
| <40% of predicted | 0.63 (0.21–1.85) | 0.40 | – | – | 0.46 (0.08–2.41) | 0.35 | – | ||||
| ≥40% of predicted | – | – | – | – | – | – | – | ||||
| DLCO (continuous) | 0.96 (0.93–1.00) | 0.08 | 0.98 (0.49–1.02) | 0.43 | 1.01 (0.96–1.07) | 0.53 | – | – | |||
| DLCO | – | ||||||||||
| <40% of predicted | 0.54 (0.14–2.03) | 0.36 | – | – | 1.45 (0.26–8.03) | 0.67 | – | ||||
| ≥40% of predicted | – | – | – | – | – | – | – | ||||
| Supplemental O2 | – | ||||||||||
| Needed | 3.43 (1.25–0.43) | 0.01 | 4.02 (0.52–30.55) | 0.17 | 0.87 (0.22–3.37) | 0.84 | – | ||||
| Not-needed | – | – | – | – | – | – | – | ||||
| KPS | – | ||||||||||
| ≤70% | 0.61 (0.23–1.62) | 0.32 | – | – | 0.68 (0.16–2.78) | 0.59 | – | ||||
| >70% | – | – | – | – | – | – | – | ||||
| CVD | – | ||||||||||
| Yes | 0.95 (0.36–2.48) | 0.92 | – | – | 0.51 (0.16–2.78) | 0.25 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| COPD | – | ||||||||||
| Yes | 0.85 (0.30–2.45) | 0.77 | – | – | 0.71 (0.20–2.46) | 0.59 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Comorbidity | – | ||||||||||
| One or more | 0.14 (0.01–1.31) | 0.08 | NA | 0.99 | 0.14 (0.01–1.54) | 0.10 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Pre-chemotherapy | – | ||||||||||
| Yes | 1.27 (0.48–3.35) | 0.62 | – | – | 0.79 (0.23–2.76) | 0.72 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post-chemotherapy | – | ||||||||||
| Yes | 1.07 (0.39–2.90) | 0.89 | – | – | 0.91 (0.28–2.93) | 0.88 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Chemotherapy | – | ||||||||||
| One or both pre or post | 1.09 (0.42–2.84) | 0.85 | – | – | 0.82 (0.23–2.92) | 0.75 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Pre-lung irradiation | – | ||||||||||
| Yes | 0.71 (0.16–3.13) | 0.65 | – | – | 0.47 (0.10–2.25) | 0.35 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Pre-lung surgery | – | ||||||||||
| Yes | 0.84 (0.27–2.60) | 0.53 | – | – | 0.31 (0.06–1.49) | 0.14 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Pre-lung treatment | – | ||||||||||
| One or both | 0.70 (0.24–2.02) | 0.51 | – | – | 0.38 (0.09–1.51) | 0.17 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Post-lung irradiation | – | ||||||||||
| Yes | 1.59 (0.36–7.07) | 0.53 | – | – | 1.2 (0.14–10.07) | 0.86 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post-lung surgery | – | ||||||||||
| Yes | 4.21 (0.50–35.27) | 0.18 | – | – | – | – | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post- lung treatment | – | ||||||||||
| One or both | 1.88 (0.42–8.32) | 0.40 | – | – | – | – | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Lung local treatment | – | ||||||||||
| One or both pre or post | 0.90 (0.34–2.38) | 0.83 | – | – | – | – | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Number of lesions | – | ||||||||||
| One lesion | 2.86 (0.97–8.39) | 0.05 | 2.00 (0.36–11.05) | 0.42 | 0.21 (0.02–1.74) | 0.15 | – | ||||
| More than one | – | – | – | – | – | – | – | ||||
| Type of primary | – | ||||||||||
| De novo | 0.70 (0.24–2.02) | 0.51 | – | – | – | – | – | ||||
| Recurrent | – | – | – | – | – | – | – | ||||
| Histology | – | ||||||||||
| Squamous | – | – | – | – | – | – | – | ||||
| Non-Squamous | 0.89 (0.34–2.34) | 0.82 | – | – | 0.61 (0.19–1.95) | 0.40 | – | ||||
| After progression | – | ||||||||||
| Salvage treatments | 2.02 (0.56–7.22) | 0.27 | – | – | – | – | – | ||||
| No treatments | – | – | – | – | – | – | – | ||||
OS, overall survival; SABR, stereotactic ablative radiotherapy; PLLs, primary lung lesions; HR, hazard ratio; FEV1, forced expiration at the first second; DLCO, diffusing capacity of the lung for carbon monoxide; KPS, Karnofsky’s performance status; CVD, cardiovascular Disease; COPD, chronic obstructive pulmonary disease.